Table I Open in new tab Detailed...

Variable

Value (range)

Distribution

Reference

Cost ($)

Chemo

2854.27 (2397.59–3310.95）

Gamma (38.11, 0.01)

(Hannouf et al., 2020)

GnRHa

4913.30 (3439.31–6387.29)

Gamma (1207.39, 0.25)

(Kwon et al., 2016)

BC surveillance per year

807.70 (646.16–969.24)

Gamma (25.00, 0.03)

(Retèl et al., 2020)

Hot flash treatment per year

97.64 (78.11–117.17)

Gamma (25.00, 0.26)

Red Book

GSM treatment first year

1839.66 (1048.61–2630.71)

Gamma (5.35, 0.003)

Red Book

GSM treatment subsequent year

1668.95 (951.30–2386.60)

Gamma (5.36, 0.003)

Red Book

OP drug treatment per year

148.02 (118.42–177.62)

Gamma (25.00, 0.17)

Red Book

Calcium and vitamin D per year

63.40 (50.72–76.08)

Gamma (25.00, 0.39)

(Weaver et al., 2019)

DXA per time

45.93 (36.74–55.12)

Gamma (25.00, 0.54)

(Agten et al., 2017)

CVD treatment first year

7410.57 (5928.46–8892.68)

Gamma (25.00, 0.003)

(Armstrong et al., 2001)

CVD treatment subsequent year

2319.57 (1855.66–2783.48)

Gamma (25.00, 0.01)

(Armstrong et al., 2001)

Pre-chemotherapy OC

15 535.59 (5304.26–19 473.41)

Gamma (25.00, 0.002)

(Devine et al., 2015; Lyttle Schumacher et al., 2017; Fuchs Weizman et al., 2021)

Cryopreservation storage per year

370.81 (134.84–2022.58)

Gamma (25.00, 0.07)

(Hirshfeld-Cytron et al., 2012)

Post-chemotherapy thaw cycle

5841.92 (3930.38–14 759.92)

Gamma (25.00, 0.004)

(Devine et al., 2015; Lyttle Schumacher et al., 2017)

Frozen embryo transfer

6066.38 (4766.54–19 074.24)

Gamma (25.00, 0.004)

(Chung et al., 2021)

Utility value

Early BC

0.94 (0.89–0.97)

Beta (0.56, 0.04)

(Lidgren et al., 2008)

Hot flash

0.73 (0.58–0.88)

Beta (6.02, 2.23)

(Kolu et al., 2015)

GSM

0.78 (0.62–0.94)

Beta (4.72, 1.33)

(Dymond et al., 2021)

0.75 (0.60–0.90)

Beta (5.50, 1.83)

(Thompson et al., 2007)

CVD

0.84 (0.79–0.90)

Beta (3.16, 0.60)

(Sun et al., 2019)

POI risk

GnRHa plus Chemo

0.09 (0.07–0.11)

Beta (22.66, 229.12)

(Del Mastro et al., 2011)

Chemo

0.26 (0.21–0.31)

Beta (18.24, 51.91)

(Del Mastro et al., 2011)

MS risk

Hot flash

0.50 (0.40–0.60)

Beta (12.00, 12.00)

(Vincent et al., 2014)

GSM

0.37 (0.30–0.44)

Beta (15.38, 26.19)

(Sukumar et al., 2021)

0.31 (0.25–0.37)

Beta (16.94, 37.71)

(Waltman et al., 2008)

CVD

0.08 (0.06–0.10)

Beta (22.92, 263.58)

(Honigberg et al., 2019)

TA risk

GnRHa plus Chemo

0.73 (0.58–0.88)

Beta (6.02, 2.23)

(Lambertini et al., 2015)

Chemo

0.64 (0.51–0.77)

Beta (8.36, 4.70)

(Lambertini et al., 2015)

TA-induced symptom risk

Hot flash

0.09 (0.07–0.11)

Beta (22.66, 229.18)

(Taylor et al., 1998)

GSM

0.21 (0.17–0.25)

Beta (19.54, 73.51)

(Sukumar et al., 2021)

Successful natural pregnancy rate

GnRHa plus Chemo

0.21 (0.17–0.25)

Beta (19.54, 73.51)

(Moore et al., 2015)

Chemo

0.11 (0.09–0.13)

Beta (22.14, 179.13)

(Moore et al., 2015)

Successful natural live birth rate

GnRHa plus Chemo

0.64 (0.51–0.77)

Beta (8.36, 4.70)

(Moore et al., 2015)

Chemo

0.50 (0.40–0.60)

Beta (12.00, 12.00)

(Moore et al., 2015)

Successful pregnancy rate

0.34 (0.27–0.41)

Beta (16.16, 31.37)

(Diaz-Garcia et al., 2018)

Successful live birth rate

0.85 (0.68–0.90)

Beta (2.90, 0.52)

(Diaz-Garcia et al., 2018)

Variable

Value (range)

Distribution

Reference

Cost ($)

Chemo

2854.27 (2397.59–3310.95）

Gamma (38.11, 0.01)

(Hannouf et al., 2020)

GnRHa

4913.30 (3439.31–6387.29)

Gamma (1207.39, 0.25)

(Kwon et al., 2016)

BC surveillance per year

807.70 (646.16–969.24)

Gamma (25.00, 0.03)

(Retèl et al., 2020)

Hot flash treatment per year

97.64 (78.11–117.17)

Gamma (25.00, 0.26)

Red Book

GSM treatment first year

1839.66 (1048.61–2630.71)

Gamma (5.35, 0.003)

Red Book

GSM treatment subsequent year

1668.95 (951.30–2386.60)

Gamma (5.36, 0.003)

Red Book

OP drug treatment per year

148.02 (118.42–177.62)

Gamma (25.00, 0.17)

Red Book

Calcium and vitamin D per year

63.40 (50.72–76.08)

Gamma (25.00, 0.39)

(Weaver et al., 2019)

DXA per time

45.93 (36.74–55.12)

Gamma (25.00, 0.54)

(Agten et al., 2017)

CVD treatment first year

7410.57 (5928.46–8892.68)

Gamma (25.00, 0.003)

(Armstrong et al., 2001)

CVD treatment subsequent year

2319.57 (1855.66–2783.48)

Gamma (25.00, 0.01)

(Armstrong et al., 2001)

Pre-chemotherapy OC

15 535.59 (5304.26–19 473.41)

Gamma (25.00, 0.002)

(Devine et al., 2015; Lyttle Schumacher et al., 2017; Fuchs Weizman et al., 2021)

Cryopreservation storage per year

370.81 (134.84–2022.58)

Gamma (25.00, 0.07)

(Hirshfeld-Cytron et al., 2012)

Post-chemotherapy thaw cycle

5841.92 (3930.38–14 759.92)

Gamma (25.00, 0.004)

(Devine et al., 2015; Lyttle Schumacher et al., 2017)

Frozen embryo transfer

6066.38 (4766.54–19 074.24)

Gamma (25.00, 0.004)

(Chung et al., 2021)

Utility value

Early BC

0.94 (0.89–0.97)

Beta (0.56, 0.04)

(Lidgren et al., 2008)

Hot flash

0.73 (0.58–0.88)

Beta (6.02, 2.23)

(Kolu et al., 2015)

GSM

0.78 (0.62–0.94)

Beta (4.72, 1.33)

(Dymond et al., 2021)

0.75 (0.60–0.90)

Beta (5.50, 1.83)

(Thompson et al., 2007)

CVD

0.84 (0.79–0.90)

Beta (3.16, 0.60)

(Sun et al., 2019)

POI risk

GnRHa plus Chemo

0.09 (0.07–0.11)

Beta (22.66, 229.12)

(Del Mastro et al., 2011)

Chemo

0.26 (0.21–0.31)

Beta (18.24, 51.91)

(Del Mastro et al., 2011)

MS risk

Hot flash

0.50 (0.40–0.60)

Beta (12.00, 12.00)

(Vincent et al., 2014)

GSM

0.37 (0.30–0.44)

Beta (15.38, 26.19)

(Sukumar et al., 2021)

0.31 (0.25–0.37)

Beta (16.94, 37.71)

(Waltman et al., 2008)

CVD

0.08 (0.06–0.10)

Beta (22.92, 263.58)

(Honigberg et al., 2019)

TA risk

GnRHa plus Chemo

0.73 (0.58–0.88)

Beta (6.02, 2.23)

(Lambertini et al., 2015)

Chemo

0.64 (0.51–0.77)

Beta (8.36, 4.70)

(Lambertini et al., 2015)

TA-induced symptom risk

Hot flash

0.09 (0.07–0.11)

Beta (22.66, 229.18)

(Taylor et al., 1998)

GSM

0.21 (0.17–0.25)

Beta (19.54, 73.51)

(Sukumar et al., 2021)

Successful natural pregnancy rate

GnRHa plus Chemo

0.21 (0.17–0.25)

Beta (19.54, 73.51)

(Moore et al., 2015)

Chemo

0.11 (0.09–0.13)

Beta (22.14, 179.13)

(Moore et al., 2015)

Successful natural live birth rate

GnRHa plus Chemo

0.64 (0.51–0.77)

Beta (8.36, 4.70)

(Moore et al., 2015)

Chemo

0.50 (0.40–0.60)

Beta (12.00, 12.00)

(Moore et al., 2015)

Successful pregnancy rate

0.34 (0.27–0.41)

Beta (16.16, 31.37)

(Diaz-Garcia et al., 2018)

Successful live birth rate

0.85 (0.68–0.90)

Beta (2.90, 0.52)

(Diaz-Garcia et al., 2018)

Table I

Open in new tab

Detailed information on model parameters.

Variable	Value (range)	Distribution	Reference
Cost ($)
Chemo	2854.27 (2397.59–3310.95）	Gamma (38.11, 0.01)	(Hannouf et al., 2020)
GnRHa	4913.30 (3439.31–6387.29)	Gamma (1207.39, 0.25)	(Kwon et al., 2016)
BC surveillance per year	807.70 (646.16–969.24)	Gamma (25.00, 0.03)	(Retèl et al., 2020)
Hot flash treatment per year	97.64 (78.11–117.17)	Gamma (25.00, 0.26)	Red Book
GSM treatment first year	1839.66 (1048.61–2630.71)	Gamma (5.35, 0.003)	Red Book
GSM treatment subsequent year	1668.95 (951.30–2386.60)	Gamma (5.36, 0.003)	Red Book
OP drug treatment per year	148.02 (118.42–177.62)	Gamma (25.00, 0.17)	Red Book
Calcium and vitamin D per year	63.40 (50.72–76.08)	Gamma (25.00, 0.39)	(Weaver et al., 2019)
DXA per time	45.93 (36.74–55.12)	Gamma (25.00, 0.54)	(Agten et al., 2017)
CVD treatment first year	7410.57 (5928.46–8892.68)	Gamma (25.00, 0.003)	(Armstrong et al., 2001)
CVD treatment subsequent year	2319.57 (1855.66–2783.48)	Gamma (25.00, 0.01)	(Armstrong et al., 2001)
Pre-chemotherapy OC	15 535.59 (5304.26–19 473.41)	Gamma (25.00, 0.002)	(Devine et al., 2015; Lyttle Schumacher et al., 2017; Fuchs Weizman et al., 2021)
Cryopreservation storage per year	370.81 (134.84–2022.58)	Gamma (25.00, 0.07)	(Hirshfeld-Cytron et al., 2012)
Post-chemotherapy thaw cycle	5841.92 (3930.38–14 759.92)	Gamma (25.00, 0.004)	(Devine et al., 2015; Lyttle Schumacher et al., 2017)
Frozen embryo transfer	6066.38 (4766.54–19 074.24)	Gamma (25.00, 0.004)	(Chung et al., 2021)
Utility value
Early BC	0.94 (0.89–0.97)	Beta (0.56, 0.04)	(Lidgren et al., 2008)
Hot flash	0.73 (0.58–0.88)	Beta (6.02, 2.23)	(Kolu et al., 2015)
GSM	0.78 (0.62–0.94)	Beta (4.72, 1.33)	(Dymond et al., 2021)
OP	0.75 (0.60–0.90)	Beta (5.50, 1.83)	(Thompson et al., 2007)
CVD	0.84 (0.79–0.90)	Beta (3.16, 0.60)	(Sun et al., 2019)
POI risk
GnRHa plus Chemo	0.09 (0.07–0.11)	Beta (22.66, 229.12)	(Del Mastro et al., 2011)
Chemo	0.26 (0.21–0.31)	Beta (18.24, 51.91)	(Del Mastro et al., 2011)
MS risk
Hot flash	0.50 (0.40–0.60)	Beta (12.00, 12.00)	(Vincent et al., 2014)
GSM	0.37 (0.30–0.44)	Beta (15.38, 26.19)	(Sukumar et al., 2021)
OP	0.31 (0.25–0.37)	Beta (16.94, 37.71)	(Waltman et al., 2008)
CVD	0.08 (0.06–0.10)	Beta (22.92, 263.58)	(Honigberg et al., 2019)
TA risk
GnRHa plus Chemo	0.73 (0.58–0.88)	Beta (6.02, 2.23)	(Lambertini et al., 2015)
Chemo	0.64 (0.51–0.77)	Beta (8.36, 4.70)	(Lambertini et al., 2015)
TA-induced symptom risk
Hot flash	0.09 (0.07–0.11)	Beta (22.66, 229.18)	(Taylor et al., 1998)
GSM	0.21 (0.17–0.25)	Beta (19.54, 73.51)	(Sukumar et al., 2021)
Successful natural pregnancy rate
GnRHa plus Chemo	0.21 (0.17–0.25)	Beta (19.54, 73.51)	(Moore et al., 2015)
Chemo	0.11 (0.09–0.13)	Beta (22.14, 179.13)	(Moore et al., 2015)
Successful natural live birth rate
GnRHa plus Chemo	0.64 (0.51–0.77)	Beta (8.36, 4.70)	(Moore et al., 2015)
Chemo	0.50 (0.40–0.60)	Beta (12.00, 12.00)	(Moore et al., 2015)
OC
Successful pregnancy rate	0.34 (0.27–0.41)	Beta (16.16, 31.37)	(Diaz-Garcia et al., 2018)
Successful live birth rate	0.85 (0.68–0.90)	Beta (2.90, 0.52)	(Diaz-Garcia et al., 2018)

Variable	Value (range)	Distribution	Reference
Cost ($)
Chemo	2854.27 (2397.59–3310.95）	Gamma (38.11, 0.01)	(Hannouf et al., 2020)
GnRHa	4913.30 (3439.31–6387.29)	Gamma (1207.39, 0.25)	(Kwon et al., 2016)
BC surveillance per year	807.70 (646.16–969.24)	Gamma (25.00, 0.03)	(Retèl et al., 2020)
Hot flash treatment per year	97.64 (78.11–117.17)	Gamma (25.00, 0.26)	Red Book
GSM treatment first year	1839.66 (1048.61–2630.71)	Gamma (5.35, 0.003)	Red Book
GSM treatment subsequent year	1668.95 (951.30–2386.60)	Gamma (5.36, 0.003)	Red Book
OP drug treatment per year	148.02 (118.42–177.62)	Gamma (25.00, 0.17)	Red Book
Calcium and vitamin D per year	63.40 (50.72–76.08)	Gamma (25.00, 0.39)	(Weaver et al., 2019)
DXA per time	45.93 (36.74–55.12)	Gamma (25.00, 0.54)	(Agten et al., 2017)
CVD treatment first year	7410.57 (5928.46–8892.68)	Gamma (25.00, 0.003)	(Armstrong et al., 2001)
CVD treatment subsequent year	2319.57 (1855.66–2783.48)	Gamma (25.00, 0.01)	(Armstrong et al., 2001)
Pre-chemotherapy OC	15 535.59 (5304.26–19 473.41)	Gamma (25.00, 0.002)	(Devine et al., 2015; Lyttle Schumacher et al., 2017; Fuchs Weizman et al., 2021)
Cryopreservation storage per year	370.81 (134.84–2022.58)	Gamma (25.00, 0.07)	(Hirshfeld-Cytron et al., 2012)
Post-chemotherapy thaw cycle	5841.92 (3930.38–14 759.92)	Gamma (25.00, 0.004)	(Devine et al., 2015; Lyttle Schumacher et al., 2017)
Frozen embryo transfer	6066.38 (4766.54–19 074.24)	Gamma (25.00, 0.004)	(Chung et al., 2021)
Utility value
Early BC	0.94 (0.89–0.97)	Beta (0.56, 0.04)	(Lidgren et al., 2008)
Hot flash	0.73 (0.58–0.88)	Beta (6.02, 2.23)	(Kolu et al., 2015)
GSM	0.78 (0.62–0.94)	Beta (4.72, 1.33)	(Dymond et al., 2021)
OP	0.75 (0.60–0.90)	Beta (5.50, 1.83)	(Thompson et al., 2007)
CVD	0.84 (0.79–0.90)	Beta (3.16, 0.60)	(Sun et al., 2019)
POI risk
GnRHa plus Chemo	0.09 (0.07–0.11)	Beta (22.66, 229.12)	(Del Mastro et al., 2011)
Chemo	0.26 (0.21–0.31)	Beta (18.24, 51.91)	(Del Mastro et al., 2011)
MS risk
Hot flash	0.50 (0.40–0.60)	Beta (12.00, 12.00)	(Vincent et al., 2014)
GSM	0.37 (0.30–0.44)	Beta (15.38, 26.19)	(Sukumar et al., 2021)
OP	0.31 (0.25–0.37)	Beta (16.94, 37.71)	(Waltman et al., 2008)
CVD	0.08 (0.06–0.10)	Beta (22.92, 263.58)	(Honigberg et al., 2019)
TA risk
GnRHa plus Chemo	0.73 (0.58–0.88)	Beta (6.02, 2.23)	(Lambertini et al., 2015)
Chemo	0.64 (0.51–0.77)	Beta (8.36, 4.70)	(Lambertini et al., 2015)
TA-induced symptom risk
Hot flash	0.09 (0.07–0.11)	Beta (22.66, 229.18)	(Taylor et al., 1998)
GSM	0.21 (0.17–0.25)	Beta (19.54, 73.51)	(Sukumar et al., 2021)
Successful natural pregnancy rate
GnRHa plus Chemo	0.21 (0.17–0.25)	Beta (19.54, 73.51)	(Moore et al., 2015)
Chemo	0.11 (0.09–0.13)	Beta (22.14, 179.13)	(Moore et al., 2015)
Successful natural live birth rate
GnRHa plus Chemo	0.64 (0.51–0.77)	Beta (8.36, 4.70)	(Moore et al., 2015)
Chemo	0.50 (0.40–0.60)	Beta (12.00, 12.00)	(Moore et al., 2015)
OC
Successful pregnancy rate	0.34 (0.27–0.41)	Beta (16.16, 31.37)	(Diaz-Garcia et al., 2018)
Successful live birth rate	0.85 (0.68–0.90)	Beta (2.90, 0.52)	(Diaz-Garcia et al., 2018)

BC, breast cancer; Chemo, chemotherapy; CVD, cardiovascular disease; DXA, dual-energy X-ray absorptiometry; GnRHa, GnRH agonist; GnRHa plus Chemo, adding GnRHa during chemotherapy; GSM, genitourinary syndrome; MS, menopausal symptoms; OC, oocyte cryopreservation; OP, osteoporosis; POI, premature ovarian insufficiency; TA, temporary amenorrhea.

This Feature Is Available To Subscribers Only